Dr. Scott Genshaft is an interventional radiologist and the Director of Community Outpatient Interventional Radiology at UCLA Health in Los Angeles, California.
Visit UCLA Health to learn more about Dr. Scott Genshaft.
Podcasts
Vascular & IR # 605Jan 9, 2026Advanced Surgical Approaches in Lung Cancer Management
Is the open thoracotomy becoming outdated as robotic surgery and advanced ablation techniques take center stage in lung cancer treatment? In the final discussion of the 2025 NSCLC Creator Weekend™ series, our virtual tumor board of interventional radiologists and pulmonologists from leading medical institutions discuss recent surgical and interventional advancements in the treatment of lung cancer.
- Vascular & IR # 603Jan 2, 2026
Biopsy & Ablation Decision-Making in Lung Cancer
Why might simultaneous ablation and biopsy be the new standard for high-probability lung cancer cases where surgery isn’t an option? In the penultimate episode of the 2025 NSCLC Creator Weekend™ series, our multidisciplinary tumor board panel discusses the intricacies and decision-making processes surrounding biopsy and ablation procedures in thoracic oncology.
- Vascular & IR # 599Dec 19, 2025
Lung Ablation: Techniques, Challenges & Best Practices
Collaboration between interventional radiology and radiation oncology has enabled high-dose brachytherapy in central lung lesions that were previously untreatable. This episode of the 2025 NSCLC Creator Weekend™ series offers a deep dive into recent advancements in lung ablation and brachytherapy techniques for primary lung cancer.
Tumor Board # 40Dec 16, 2025Advanced Surgical Approaches in Lung Cancer Management
Is the open thoracotomy becoming outdated as robotic surgery and advanced ablation techniques take center stage in lung cancer treatment? In the final discussion of the 2025 NSCLC Creator Weekend™ series, our virtual tumor board of interventional radiologists and pulmonologists from leading medical institutions discuss recent surgical and interventional advancements in the treatment of lung cancer.
- Vascular & IR # 597Dec 12, 2025
Ablative Treatments & Radiotherapy: The Latest in Lung Cancer Treatment
Why might the standard RECIST criteria fail to accurately track success after tumor ablation, and what should you look for instead? In the 4th installment of the 2025 NSCLC Creator Weekend™ series, hosts Drs. Scott Genshaft and Kavi Krishnasamy are joined by specialists from UCLA and USC to discuss and debate advanced treatment options for primary lung cancer.
- Tumor Board # 39Dec 9, 2025
Biopsy & Ablation Decision-Making in Lung Cancer
Why might simultaneous ablation and biopsy be the new standard for high-probability lung cancer cases where surgery isn’t an option? In the penultimate episode of the 2025 NSCLC Creator Weekend™ series, our multidisciplinary tumor board panel discusses the intricacies and decision-making processes surrounding biopsy and ablation procedures in thoracic oncology.
- Vascular & IR # 595Dec 5, 2025
Lung Cancer Staging & Systemic Therapies: Recent Advancements
How do leading oncologists interpret the abundance of molecular tests, genomic data, and biomarkers to create a lung cancer patient’s treatment plan? In this episode of the 2025 NSCLC Creator Weekend™ series, our tumor board discusses the complexities of lung cancer treatment, including new systemic therapies, lung cancer staging, and the role of molecular diagnostics and liquid biopsies.
- Tumor Board # 38Dec 2, 2025
Lung Ablation: Techniques, Challenges & Best Practices
Collaboration between interventional radiology and radiation oncology has enabled high-dose brachytherapy in central lung lesions that were previously untreatable. This episode of the 2025 NSCLC Creator Weekend™ series offers a deep dive into recent advancements in lung ablation and brachytherapy techniques for primary lung cancer.
- Tumor Board # 37Nov 25, 2025
Ablative Treatments & Radiotherapy: The Latest in Lung Cancer Treatment
Why might the standard RECIST criteria fail to accurately track success after tumor ablation, and what should you look for instead? In the 4th installment of the 2025 NSCLC Creator Weekend™ series, hosts Drs. Scott Genshaft and Kavi Krishnasamy are joined by specialists from UCLA and USC to discuss and debate advanced treatment options for primary lung cancer.
- Vascular & IR # 591Nov 21, 2025
NSCLC Tumor Board Discussion: Considerations for Oligometastatic Disease
When cancer spreads to the brain, what is the best approach: immediate local treatment or systemic immunotherapy first? Part two of the 2025 NSCLC Creator Weekend™ series focuses on a complex case involving a 75-year-old woman with a history of breast malignancy, presenting with new dyspnea and a large mass in the left lower lobe.
- Tumor Board # 36Nov 18, 2025
Lung Cancer Staging & Systemic Therapies: Recent Advancements
How do leading oncologists interpret the abundance of molecular tests, genomic data, and biomarkers to create a lung cancer patient’s treatment plan? In this episode of the 2025 NSCLC Creator Weekend™ series, our tumor board discusses the complexities of lung cancer treatment, including new systemic therapies, lung cancer staging, and the role of molecular diagnostics and liquid biopsies.
- Vascular & IR # 589Nov 14, 2025
Lung Cancer Tumor Boards: Multidisciplinary Approaches & Best Practices
As lung cancer treatments become more complex, is a collaborative tumor board more essential than ever? We’re kicking off the 2025 NSCLC Creator Weekend™ series with an in-studio panel discussion on the multidisciplinary management of lung cancer. The panel includes experts from medical oncology, thoracic surgery, radiation oncology, and interventional pulmonology from major institutions in Los Angeles.
- Tumor Board # 35Nov 14, 2025
NSCLC Tumor Board Discussion: Considerations for Oligometastatic Disease
When cancer spreads to the brain, what is the best approach: immediate local treatment or systemic immunotherapy first? Part two of the 2025 NSCLC Creator Weekend™ series focuses on a complex case involving a 75-year-old woman with a history of breast malignancy, presenting with new dyspnea and a large mass in the left lower lobe.
- Tumor Board # 34Nov 11, 2025
Lung Cancer Tumor Boards: Multidisciplinary Approaches & Best Practices
As lung cancer treatments become more complex, is a collaborative tumor board more essential than ever? We’re kicking off the 2025 NSCLC Creator Weekend™ series with an in-studio panel discussion on the multidisciplinary management of lung cancer. The panel includes experts from medical oncology, thoracic surgery, radiation oncology, and interventional pulmonology from major institutions in Los Angeles.